• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Medtronic Diabetes to lay off 81 employees ahead of MiniMed separation

February 20, 2026 By Sean Whooley

Medtronic World Diabetes Day
[Image from Medtronic]
Medtronic (NYSE:MDT) is cutting 81 jobs from its Diabetes unit ahead of its planned separation into MiniMed.

A Worker Adjustment and Retraining Notification (WARN) notice filed in California confirms the company’s plans to lay off 81 employees at its Northridge facility. MedTech Dive reported the news first.

The notice states that Medtronic notified the state of the planned workforce reduction on Feb. 5, 2026. It plans for the layoffs to go into effect on April 7, 2026.

According to the MedTech Dive report, the restructuring of operations affects engineering, IT, marketing and technician roles. As of last year, the Diabetes business had a team of more than 8,000 global employees, meaning the layoffs affect around 1% of the unit’s global workforce.

The layoffs come as Medtronic looks to separate the Diabetes business into a publicly traded company called MiniMed.

A Medtronic spokesperson shared the following statement with Drug Delivery Business News:

“As we prepare for Diabetes to operate as a standalone, public company, we need to ensure the right structure, capabilities, and scale for the business to succeed. This includes sharpening focus, aligning resources to the most critical priorities, and in some cases, bringing in new skills and expertise. While difficult, these decisions ensure we’re setting this business up for long-term success.”

MiniMed is currently working toward completing an IPO, for which it filed at the end of 2025, and bringing new insulin pump technology to the market. Medtronic said earlier this week that it submitted the next-generation MiniMed Flex to the FDA for approval.

The medtech giant announced in May 2025 that it planned to separate the Diabetes unit into a standalone, publicly traded company. The move sought to create “a more focused Medtronic” with a more simplified portfolio in high-margin growth markets. At the same time, it creates an independent, scaled leader in diabetes. Over the last nine months, Medtronic continues to state that the process — which it expected to complete within 18 months — is proceeding as planned. It expects to get the IPO-driven separation done by the end of the calendar year.

MassDevice has tracked layoffs around the industry since mid-2022. Read more about those layoffs here.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: Medtronic, minimed

IN CASE YOU MISSED IT

  • BD’s IV catheters plant in Utah marks 70 years
  • Novo taps Nanexa for long-acting obesity injectables with €1.17B pact
  • Abbott partners with Berry Street to add nutrition coaching to Lingo
  • Dexcom CFO to expand into COO role
  • Beta Bionics insulin patch pump scores FDA clearance

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS